Could a common diabetes drug speed up heart and kidney healing?

NCT ID NCT06111768

Completed Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether a diabetes drug called dapagliflozin can help people with heart failure who also develop kidney injury recover faster. About 30 adults will take the drug or usual care for three days. The main goal is to see if a larger trial is possible, not to prove the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that lowers blood sugar and protects the kidneys)
What this could lead to: If it works, this could point toward a new way to help people with heart failure and kidney injury recover faster.
What could go wrong: This is a very small, early feasibility study with only 30 people. It is designed to see if a larger trial is possible, not to prove the drug works. The drug may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIORENAL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardio-renal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIORENAL SYNDROME

Contacts and locations

Locations

Yale New Haven Hospital

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.